Armata Pharmaceuticals, Inc. (ARMP) Stock Forecast
ARMP analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $17.50 average of analyst targets
- Upside to target
- +419.3% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.57
- 52-week range
- $2.78 – $14.80
ARMP analyst ratings
1 analystsNumber of analysts at each rating.
ARMP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ARMP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.57 | −$0.54 | −$0.74 | +25.0% | 2 |
| Current fiscal year (2026) | −$1.86 | −$2.27 | −$1.46 | −$4.80 | +61.2% | 2 |
| Next fiscal year (2027) | −$1.45 | −$2.04 | −$0.85 | −$1.86 | +22.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ARMP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $450,000 | $0 | $900,000 | −61.2% | 2 |
| Current fiscal year (2026) | $4.2M | $3.3M | $5.2M | −13.3% | 2 |
| Next fiscal year (2027) | $2.8M | $0 | $5.5M | −35.3% | 2 |
ARMP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ARMP revenue: reported and forecast
ARMP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.39 | −$0.57 | −$0.56 | −$0.56 | +42.3% | 0 up · 2 down |
| Current fiscal year (2026) | −$3.81 | −$3.81 | −$2.27 | −$1.86 | −$1.86 | −51.0% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.34 | −$1.34 | −$1.40 | −$1.45 | −$1.45 | +7.8% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ARMP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ARMP beat in 6 of 12.
What analysts expect from ARMP
1 analysts cover Armata Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.50, 419.3% above the latest close of $3.37. Analysts expect earnings of −$1.86 per share for 2026, +61.2% from a year earlier. For 2027 the average estimate is −$1.45 per share on revenue of $2.8 million. Armata Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: ARMP income statement, ARMP key metrics, ARMP chart. See the ARMP stock overview for the latest quote and news.
ARMP forecast FAQ
What is Armata Pharmaceuticals's price target?
The average analyst price target for Armata Pharmaceuticals is $17.50, 419.3% above the latest close of $3.37.
Is Armata Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Armata Pharmaceuticals, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Armata Pharmaceuticals's EPS forecast?
Analysts forecast −$1.86 per share for 2026 (range −$2.27 to −$1.46); for 2027 the estimate is −$1.45.
What is Armata Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $4.2 million, growth of −13.3%; for 2027 it is $2.8 million.
When does Armata Pharmaceuticals report earnings?
Armata Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.57.
Does Armata Pharmaceuticals usually beat earnings estimates?
Armata Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.